黃芪對心氣陽虛證擴張型心肌病患者的干預作用及對抗心肌抗體的影響
發(fā)布時間：2019-07-23 10:48
【摘要】：目的:觀察黃芪顆粒劑對心氣虛和(或)陽虛證素的擴張型心肌病(dilated cardiomyopathy,DCM)患者干預作用及對抗心肌抗體的影響,為黃芪的臨床應用提供理論依據(jù)。方法:選擇無錫市中醫(yī)醫(yī)院和無錫市人民醫(yī)院2013年5月至2016年1月期間住院的DCM心氣虛和(或)陽虛證素患者134例為DCM組,隨機分為常規(guī)組(采用西醫(yī)常規(guī)治療)67例,中藥組(在常規(guī)組治療基礎上+黃芪60 g)67例。并隨機抽取30例健康體檢者作為正常組。在治療第1,28天觀察N終端腦鈉肽(NT-pro BNP),左室射血分數(shù)(LVEF),左室舒張期末內(nèi)徑(LVEDD),抗心肌抗體抗β1腎上腺能受體自身抗體(ant-β1),抗肌球蛋白重鏈自身抗體(ant-MHC),抗毒蕈堿-2受體自身抗體(ant-M2),抗腺嘌呤核苷(ADP/ATP)轉位酶自身抗體(ant-ANT)水平,臨床癥狀、體征、紐約心臟病協(xié)會(NYHA)心功能分級等的變化。結果:臨床療效,中藥組患者中醫(yī)證候療效總有效率為91.9%,常規(guī)組患者中醫(yī)證候療效總有效率為71.0%,中藥組高于常規(guī)組(P0.05)。心功能,中藥組與常規(guī)組患者治療后NYHA分級的療效總有效率分別為82.3%,83.9%,兩組比較差異無統(tǒng)計學意義。中藥組治療后NT-pro BNP水平低于常規(guī)組同期水平(P0.05)。治療后兩組LVEF明顯升高(P0.05);LVEDD明顯下降(P0.05)。兩組治療后各指標差異無統(tǒng)計學意義�？剐募】贵w,與正常組比較,DCM組各抗心肌抗體明顯升高(P0.05)。治療后兩組患者血清抗心肌抗體ant-β1,ant-MHC,ant-M2水平明顯降低(P0.05),中藥組治療后ant-ANT水平較治療前顯著降低(P0.05)。中藥組治療后ANT水平低于常規(guī)組同期水平(P0.05)。中藥組低血壓及心律失常發(fā)生率低于常規(guī)組(P0.05)。兩組腎功能不全及刺激性干咳發(fā)生率無統(tǒng)計學差異。結論:黃芪能調(diào)節(jié)心氣虛和(或)陽虛證素的DCM患者抗心肌抗體水平,降低血清NT-pro BNP水平,提高中醫(yī)證候療效,減輕患者癥狀,改善心功能,減少不良事件的發(fā)生。
[Abstract]:Objective: to observe the intervention effect of Huangqi granule on dilated cardiomyopathy (dilated cardiomyopathy,DCM) patients with deficiency of heart qi and / or yang deficiency syndrome and the effect of anti-myocardial antibody, so as to provide theoretical basis for clinical application of Astragalus membranaceus. Methods: from May 2013 to January 2016, 134 patients with DCM heart qi deficiency and / or yang deficiency syndrome hospitalized in Wuxi traditional Chinese Medicine Hospital and Wuxi people's Hospital were randomly divided into routine group (67 cases treated with routine western medicine) and traditional Chinese medicine group (60 g astragalus membranaceus 60 g on the basis of routine treatment). The patients with heart qi deficiency and / or yang deficiency syndrome were randomly divided into routine group (67 cases) and traditional Chinese medicine group (60 g astragalus membranaceus group). 30 healthy subjects were randomly selected as normal group. On the 1st and 28th day of treatment, the levels of N terminal brain natriuretic peptide (NT-pro BNP), left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), anti-myocardial antibody anti-尾 1 suprarenal adenoreceptor autoantibody (ant- 尾 1), anti myosin heavy chain autoantibody (ant-MHC), anti muscarinic 2 receptor autoantibody (ant-M2), anti adenine nucleosides (ADP/ATP) translocation enzyme autoantibody (ant-ANT) were observed on the 1st and 28th day of treatment. Signs, changes in (NYHA) cardiac function classification of the New York Heart Association. Results: the total effective rate of TCM syndrome in traditional Chinese medicine group was 91.9%, and that in routine group was 71.0%. The total effective rate of TCM syndrome in traditional Chinese medicine group was higher than that in routine group (P 0.05). The total effective rate of NYHA grading in traditional Chinese medicine group and routine group was 82.3% and 83.9%, respectively. there was no significant difference between the two groups. After treatment, the level of NT-pro BNP in the traditional Chinese medicine group was lower than that in the routine group (P 0.05). After treatment, LVEF in the two groups increased significantly (P 0.05,); LVEDD decreased significantly (P 0.05). There was no significant difference in the indexes between the two groups after treatment. Compared with the normal group, the anti-myocardial antibodies in DCM group were significantly higher than those in the normal group (P 0.05). After treatment, the levels of serum anti-myocardial antibody ant- 尾 1 and ant-MHC,ant-M2 in the two groups were significantly lower than those before treatment (P 0.05), and the levels of ant-ANT in the traditional Chinese medicine group were significantly lower than those before treatment (P 0.05). After treatment, the level of ANT in the traditional Chinese medicine group was lower than that in the routine group (P 0.05). The incidence of hypotension and arrhythmia in the traditional Chinese medicine group was lower than that in the routine group (P 0.05). There was no significant difference in the incidence of renal insufficiency and irritating dry cough between the two groups. Conclusion: Astragalus membranaceus can regulate the level of anti-myocardial antibody in DCM patients with heart-qi deficiency and / or yang deficiency syndrome, reduce the level of serum NT-pro BNP, improve the curative effect of TCM syndrome, alleviate the symptoms of patients, improve cardiac function and reduce the occurrence of adverse events.
【作者單位】： 南京中醫(yī)藥大學無錫附屬醫(yī)院;無錫市惠山區(qū)中醫(yī)院;
【基金】：無錫市醫(yī)院管理中心科研項目(YGZXM14047)
【分類號】：R259
[Abstract]:Objective: to observe the intervention effect of Huangqi granule on dilated cardiomyopathy (dilated cardiomyopathy,DCM) patients with deficiency of heart qi and / or yang deficiency syndrome and the effect of anti-myocardial antibody, so as to provide theoretical basis for clinical application of Astragalus membranaceus. Methods: from May 2013 to January 2016, 134 patients with DCM heart qi deficiency and / or yang deficiency syndrome hospitalized in Wuxi traditional Chinese Medicine Hospital and Wuxi people's Hospital were randomly divided into routine group (67 cases treated with routine western medicine) and traditional Chinese medicine group (60 g astragalus membranaceus 60 g on the basis of routine treatment). The patients with heart qi deficiency and / or yang deficiency syndrome were randomly divided into routine group (67 cases) and traditional Chinese medicine group (60 g astragalus membranaceus group). 30 healthy subjects were randomly selected as normal group. On the 1st and 28th day of treatment, the levels of N terminal brain natriuretic peptide (NT-pro BNP), left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), anti-myocardial antibody anti-尾 1 suprarenal adenoreceptor autoantibody (ant- 尾 1), anti myosin heavy chain autoantibody (ant-MHC), anti muscarinic 2 receptor autoantibody (ant-M2), anti adenine nucleosides (ADP/ATP) translocation enzyme autoantibody (ant-ANT) were observed on the 1st and 28th day of treatment. Signs, changes in (NYHA) cardiac function classification of the New York Heart Association. Results: the total effective rate of TCM syndrome in traditional Chinese medicine group was 91.9%, and that in routine group was 71.0%. The total effective rate of TCM syndrome in traditional Chinese medicine group was higher than that in routine group (P 0.05). The total effective rate of NYHA grading in traditional Chinese medicine group and routine group was 82.3% and 83.9%, respectively. there was no significant difference between the two groups. After treatment, the level of NT-pro BNP in the traditional Chinese medicine group was lower than that in the routine group (P 0.05). After treatment, LVEF in the two groups increased significantly (P 0.05,); LVEDD decreased significantly (P 0.05). There was no significant difference in the indexes between the two groups after treatment. Compared with the normal group, the anti-myocardial antibodies in DCM group were significantly higher than those in the normal group (P 0.05). After treatment, the levels of serum anti-myocardial antibody ant- 尾 1 and ant-MHC,ant-M2 in the two groups were significantly lower than those before treatment (P 0.05), and the levels of ant-ANT in the traditional Chinese medicine group were significantly lower than those before treatment (P 0.05). After treatment, the level of ANT in the traditional Chinese medicine group was lower than that in the routine group (P 0.05). The incidence of hypotension and arrhythmia in the traditional Chinese medicine group was lower than that in the routine group (P 0.05). There was no significant difference in the incidence of renal insufficiency and irritating dry cough between the two groups. Conclusion: Astragalus membranaceus can regulate the level of anti-myocardial antibody in DCM patients with heart-qi deficiency and / or yang deficiency syndrome, reduce the level of serum NT-pro BNP, improve the curative effect of TCM syndrome, alleviate the symptoms of patients, improve cardiac function and reduce the occurrence of adverse events.
【作者單位】： 南京中醫(yī)藥大學無錫附屬醫(yī)院;無錫市惠山區(qū)中醫(yī)院;
【基金】：無錫市醫(yī)院管理中心科研項目(YGZXM14047)
【分類號】：R259
【參考文獻】
相關期刊論文 前6條
1 陸曙;戴飛;;《靈樞》“心脹”探析[J];中華中醫(yī)藥雜志;2013年11期
2 雷宏飛;;黃芪注射液聯(lián)合依那普利治療擴張型心肌病30例[J];吉林醫(yī)學;2011年27期
3 周愛明;吳雄杰;陳衛(wèi)朝;袁潔青;張建強;;大劑量黃芪治療擴張型心肌病合并心力衰竭的臨床觀察[J];浙江中醫(yī)雜志;2011年01期
4 李季泓;;黃芪的藥理作用研究[J];遼寧中醫(yī)藥大學學報;2009年04期
5 ;心肌病診斷與治療建議[J];中華心血管病雜志;2007年01期
6 周吉燕,樊懿,孔建龍,吳大正,胡之璧;黃芪中不同提取成分對在體大鼠心肌缺血-再灌注損傷的心功能影響[J];中國中藥雜志;2000年05期
相關碩士學位論文 前1條
1 潘茜;擴張型心肌病中醫(yī)證素及其與心功能指標和抗心肌抗體相關性的研究[D];南京中醫(yī)藥大學;2013年
【共引文獻】
相關期刊論文 前10條
1 謝亞闖;諶小麗;董新博;;心臟磁共振釓對比劑延遲強化對擴張型心肌病患者心臟不良事件的預測價值研究[J];實用心腦肺血管病雜志;2017年06期
2 白志冬;劉麗華;黨濤;喬樹洲;王煜;;生脈保元湯加味對擴張型心肌病合并心力衰竭患者心功能及血清BNP、CA125的影響[J];現(xiàn)代中西醫(yī)結合雜志;2017年19期
3 陸曙;沈麗娟;任春;朱紅俊;楊慶有;;擴張型心肌病患者中醫(yī)證素與抗心肌抗體的相關性[J];中國實驗方劑學雜志;2017年18期
4 沈麗娟;戴飛;陸曙;周春剛;李嵐;周永華;楊慶有;;苓桂養(yǎng)心湯對擴張型心肌病大鼠心肌保護作用及肌漿網(wǎng)鈣調(diào)控蛋白的影響[J];中國實驗方劑學雜志;2017年18期
5 李平;;急性心肌梗死患者直接PCI治療中應用瑞舒伐他汀配合地爾硫卓的效果觀察[J];醫(yī)學理論與實踐;2017年11期
6 沈麗娟;陸曙;陸曉o，
本文編號：2518104
本文鏈接：http://www.lk138.cn/zhongyixuelunwen/2518104.html
最近更新
教材專著
